Prucalopride - MOTEGRITY official label | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

MOTEGRITY: measured clearance and a separate official-source recovery

The official renal study used 24-hour urinary measured creatinine clearance. The short RX rendering did not supply its renal instructions and remains held.

Before applying: Keep the official supplement and dialysis avoidance separate from the incomplete RX page. Do not silently relabel measured clearance as Cockcroft-Gault or indexed eGFR.

Also check: MOTEGRITY: measured clearance and a separate official-source recovery

Official source

Prucalopride - MOTEGRITY official label

Product / population: Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.
Renal measure: Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR.

Separate official source supplement. The MOTEGRITY RX rendering contains description only and remains held; this is not an RX recovery.

Renal dosing, restrictions and evidence limits

For adults with chronic idiopathic constipation, the dose is 2 mg once daily; at CrCl <30 mL/min, reduce to 1 mg once daily. No adjustment is required at CrCl >=30. Avoid use in ESRD requiring dialysis. The renal trial used CrCl determined by 24-hour urine collection, not an automatically assumed Cockcroft-Gault estimate. Assess intestinal contraindications and monitor new or worsening depression or suicidal symptoms; renal reduction does not remove these precautions.

Source revision: Prescribing information revised 7/2025. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bca1e4c6-4b2b-4876-8ab3-654629c4ff1b

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Prucalopride - MOTEGRITY official label

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.

Renal method: Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

MOTEGRITY: measured clearance and a separate official-source recovery

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

boundary units

MOTEGRITY: measured clearance and a separate official-source recovery

The official renal study used 24-hour urinary measured creatinine clearance. The short RX rendering did not supply its renal instructions and remains held.

How to use this: Keep the official supplement and dialysis avoidance separate from the incomplete RX page. Do not silently relabel measured clearance as Cockcroft-Gault or indexed eGFR.

Prucalopride - MOTEGRITY official label

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Prucalopride - MOTEGRITY official label

Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.

Method: Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Prucalopride - MOTEGRITY official label

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bca1e4c6-4b2b-4876-8ab3-654629c4ff1b

Exact product and population

Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.

RDM47-SCOPE-prucalopride-motegrity · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Prucalopride - MOTEGRITY official label

Open original reference

Open / share this exact local source

DailyMed / Takeda Pharmaceuticals America, Inc. · Prucalopride - MOTEGRITY official label; selected renal source sections only, not a complete prescribing monograph.

Renal method: Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR.
Source date: Prescribing information revised 7/2025.
Retrieved: 2026-09-08

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM47-official-prucalopride-motegrity-4a36a17b47-C1 · Source locator: Sections 2, 5.1 and 8.6; lines 271-296, 403-408.

Source-specific limits

Separate official source supplement. The MOTEGRITY RX rendering contains description only and remains held; this is not an RX recovery.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bca1e4c6-4b2b-4876-8ab3-654629c4ff1b
Retrieved: 2026-09-08
Exact label title: Prucalopride - MOTEGRITY official label
DailyMed Set ID: bca1e4c6-4b2b-4876-8ab3-654629c4ff1b
Labeler: Takeda Pharmaceuticals America, Inc.
DailyMed page updated: 2025-07-17
Label revision: Prescribing information revised 7/2025.
Renal-function method: Measured CrCl, mL/min, from 24-hour urine collection in the renal trial. Not automatically Cockcroft-Gault or indexed eGFR.
Source date/version: Prescribing information revised 7/2025.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 7b16ce91d3a4b859e7ad0fb102674631784c5b99395bea59158c20535d35b421

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bca1e4c6-4b2b-4876-8ab3-654629c4ff1b
Source retrieval: 2026-09-08. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: b6d193d243c900451c61b81d9b63496389062fb1b83ffd4f97f56920adc1272b
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report